Geode Capital Management LLC Buys 5,771 Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Geode Capital Management LLC raised its position in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 4.8% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 124,761 shares of the medical instruments supplier’s stock after purchasing an additional 5,771 shares during the period. Geode Capital Management LLC’s holdings in Mesa Laboratories were worth $16,205,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of MLAB. Canada Pension Plan Investment Board bought a new position in Mesa Laboratories during the second quarter valued at $26,000. FMR LLC lifted its position in shares of Mesa Laboratories by 34.1% during the third quarter. FMR LLC now owns 393 shares of the medical instruments supplier’s stock worth $51,000 after acquiring an additional 100 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of Mesa Laboratories in the third quarter valued at $70,000. Sanctuary Advisors LLC purchased a new stake in shares of Mesa Laboratories in the second quarter worth about $183,000. Finally, Berry Wealth Group LP bought a new stake in Mesa Laboratories during the 3rd quarter worth approximately $204,000. Institutional investors own 90.60% of the company’s stock.

Mesa Laboratories Price Performance

MLAB stock opened at $133.06 on Monday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.51 and a current ratio of 0.70. The firm has a market cap of $722.65 million, a P/E ratio of -2.92 and a beta of 0.86. The firm’s fifty day moving average is $120.56 and its 200 day moving average is $117.45. Mesa Laboratories, Inc. has a 52 week low of $83.68 and a 52 week high of $141.17.

Mesa Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 16th. Investors of record on Friday, November 29th were given a dividend of $0.16 per share. The ex-dividend date was Friday, November 29th. This represents a $0.64 annualized dividend and a yield of 0.48%. Mesa Laboratories’s payout ratio is -1.40%.

Insider Buying and Selling at Mesa Laboratories

In related news, CEO Gary M. Owens sold 2,518 shares of the firm’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $113.62, for a total value of $286,095.16. Following the sale, the chief executive officer now directly owns 45,888 shares of the company’s stock, valued at $5,213,794.56. This trade represents a 5.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 4.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on MLAB. Evercore ISI lifted their target price on shares of Mesa Laboratories from $120.00 to $160.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. StockNews.com cut Mesa Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, November 13th.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.